ATOS - Atossa Genetics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.31
+0.14 (+6.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.17
Open2.17
Bid2.26 x 1000
Ask2.35 x 1000
Day's Range2.17 - 2.35
52 Week Range2.01 - 19.08
Volume78,020
Avg. Volume178,190
Market Cap6.503M
Beta4.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire3 days ago

    Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

    SEATTLE, Aug. 13, 2018-- Atossa Genetics Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced ...

  • ACCESSWIRE15 days ago

    The Groundwork Forum Podcast Publishes "An Overview of Breast Cancer Treatment Innovator Atossa Genetics"

    SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2018 / The Groundwork Forum Podcas t aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives ...

  • GlobeNewswire15 days ago

    Atossa Genetics Contracts with Additional Manufacturer of Endoxifen

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that is has added Alchem Laboratories as a U.S. contract manufacturer to supply Endoxifen.

  • GlobeNewswire16 days ago

    Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mueller ...

  • GlobeNewswire17 days ago

    Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences — Discovering Underlying Factors of Influence

    NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NetApp, ...

  • ACCESSWIRE22 days ago

    Vista Partners Publishes July's Macroeconomic & Investment Newsletter

    SAN FRANCISCO, CA / ACCESSWIRE / July 25, 2018 / Vista Partners ("Vista") has published July's FREE Macroeconomic & Investment Monthly Newsletter, "Economy & Market Maintaining Highs." ...

  • GlobeNewswire29 days ago

    Atossa Genetics Announces Intraductal Microcatheter ImmunoOncology Pre-Clinical Program

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it is advancing its intraductal microcatheter immunotherapy program with pre-clinical studies being conducted by Translational Drug Development, LLC (“TD2”). “While there has been recent success treating blood cancers with chimeric antigen receptor therapy (or, CAR-T), there has not been much success using CAR-T to treat solid tumors like breast cancer,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa.

  • GlobeNewswirelast month

    Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened a Phase 2 study of its proprietary oral Endoxifen to treat breast cancer in the “window of opportunity” setting, which is the period between diagnosis of breast cancer and surgery. “Once a patient is diagnosed with breast cancer, there is a window of time, typically a number of weeks, before definitive surgery is performed,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in estrogen-receptor-positive patients during this ‘window of opportunity.' Tamoxifen, the current standard of care, has not been effective in this setting, probably because it can take 50-200 days to reach steady-state of Endoxifen blood levels, while the surgery is usually completed within 30 to 45 days of diagnosis.

  • ACCESSWIRE2 months ago

    ''Strong Economy, Trade Wars & Market Volatility''

    SAN FRANCISCO, CA / ACCESSWIRE / June 27, 2018 / Vista Partners ("Vista") has published June's FREE Macroeconomic & Investment Monthly Newsletter, "Strong Economy, Trade Wars & Market Volatility." ...

  • GlobeNewswire2 months ago

    Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened its Phase 2 study of proprietary topical Endoxifen on mammographic breast density, or MBD, reduction. Studies by others have shown that a reduction in MBD reduces the risk of developing breast cancer and may potentially improve the accuracy of mammography in finding cancer.

  • GlobeNewswire2 months ago

    Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has completed dosing and clinical visits in its Phase 1 study of its proprietary topical Endoxifen in men. “We are now proceeding to the final stages of this study, which are to complete analysis of blood samples and then collect and analyze the data,” commented Steve Quay, Ph.D., M.D., President and CEO of Atossa. Atossa is developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement.

  • GlobeNewswire2 months ago

    Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the appointment of two additional pharmaceutical executives to its strategic advisory board. The board will play a key role in a number of important strategic initiatives in accelerating the clinical development of Atossa’s programs. The company has named former Pfizer executive, Dr. Makarand (Mak) Jawadekar and Dr. Ajit Shetty, Chairman of the Belgium-based Flemish Institute of Biotechnology and former Janssen Pharmaceutica NV executive, to Atossa’s strategic advisory board.

  • ACCESSWIRE3 months ago

    "The Balancing Act"

    SAN FRANCISCO, CA / ACCESSWIRE / May 31, 2018 / Vista Partners ("Vista") has published May's FREE Macroeconomic & Investment Monthly Newsletter titled "The Balancing Act." Vista's monthly ...

  • GlobeNewswire3 months ago

    Atossa Announces $13.4 Million in Expected Gross Proceeds from Recently Expired Rights Offering

    Atossa Genetics Inc. ("Atossa" or "the Company") announced today that the Company’s previously announced rights offering (“the Rights Offering”) expired on Thursday, May 24, 2018 and these rights are no longer exercisable. The Company accepted all valid subscriptions that were presented and estimates that the Rights Offering will result in approximately $13.4 million in gross proceeds. The results of the Rights Offering and Atossa’s estimates regarding the aggregate gross proceeds of the Rights Offering to be received by Atossa are subject to finalization and verification by Atossa and its subscription agent.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Atossa Genetics and SteadyMed

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Pharma stocks Atossa Genetics and SteadyMed were seeing big gains in Monday trading after each company announced big news. Atossa has received approval from the ...

  • ACCESSWIRE4 months ago

    "U.S. Economy Remains Strong, Anticipating Steady Growth with Rate Twist"

    SAN FRANCISCO, CA / ACCESSWIRE / April 26, 2018 / Vista Partners ("Vista") has published April's FREE Macroeconomic & Investment Monthly Newsletter, "U.S. Economy Remains Strong, Anticipating ...